> top > docs > PMC:7073332 > spans > 28276-29388 > annotations

PMC:7073332 / 28276-29388 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
803 832-849 Gene denotes estrogen receptor Gene:2099
804 386-399 Gene denotes Drugs A and B
805 291-296 Species denotes human Tax:9606
806 36-40 Species denotes HCoV Tax:694448
807 228-232 Species denotes HCoV Tax:694448
808 416-420 Species denotes HCoV Tax:694448
809 769-775 Disease denotes tumors MESH:D009369
810 916-933 Disease denotes polycystic kidney MESH:D007690
811 993-1015 Disease denotes rhythm sleep disorders MESH:D012893

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T140 52-59 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T141 720-723 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T142 832-840 Body_part denotes estrogen http://purl.org/sig/ont/fma/fma83376
T143 927-933 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T144 942-951 Body_part denotes melatonin http://purl.org/sig/ont/fma/fma74644
T145 955-969 Body_part denotes biogenic amine http://purl.org/sig/ont/fma/fma67161

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T7 927-933 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T122 769-775 Disease denotes tumors http://purl.obolibrary.org/obo/MONDO_0005070
T123 983-1015 Disease denotes circadian rhythm sleep disorders http://purl.obolibrary.org/obo/MONDO_0024361
T124 1000-1015 Disease denotes sleep disorders http://purl.obolibrary.org/obo/MONDO_0003406

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T205 0-1 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T206 291-296 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T207 392-393 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T208 398-399 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T209 405-406 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T210 503-504 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T211 514-518 http://purl.obolibrary.org/obo/CLO_0001869 denotes B. b
T212 606-607 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T213 619-620 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T214 832-849 http://purl.obolibrary.org/obo/PR_000007204 denotes estrogen receptor
T215 927-933 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T216 927-933 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T217 927-933 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T218 953-954 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T314 52-59 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T315 83-87 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T316 115-119 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T317 209-214 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T318 587-591 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T319 608-617 Chemical denotes sirolimus http://purl.obolibrary.org/obo/CHEBI_9168
T320 628-645 Chemical denotes immunosuppressant http://purl.obolibrary.org/obo/CHEBI_35705
T321 656-666 Chemical denotes antifungal http://purl.obolibrary.org/obo/CHEBI_35718
T322 671-685 Chemical denotes antineoplastic http://purl.obolibrary.org/obo/CHEBI_35610
T323 734-743 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T324 780-790 Chemical denotes toremifene http://purl.obolibrary.org/obo/CHEBI_9635
T325 832-859 Chemical denotes estrogen receptor modulator http://purl.obolibrary.org/obo/CHEBI_50739
T326 832-840 Chemical denotes estrogen http://purl.obolibrary.org/obo/CHEBI_50114
T327 841-859 Chemical denotes receptor modulator http://purl.obolibrary.org/obo/CHEBI_90710
T328 866-872 Chemical denotes emodin http://purl.obolibrary.org/obo/CHEBI_42223|http://purl.obolibrary.org/obo/CHEBI_77659
T330 890-894 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T331 942-951 Chemical denotes melatonin http://purl.obolibrary.org/obo/CHEBI_16796
T332 964-969 Chemical denotes amine http://purl.obolibrary.org/obo/CHEBI_32952
T333 1022-1036 Chemical denotes mercaptopurine http://purl.obolibrary.org/obo/CHEBI_50667
T334 1041-1055 Chemical denotes antimetabolite http://purl.obolibrary.org/obo/CHEBI_35221
T335 1056-1076 Chemical denotes antineoplastic agent http://purl.obolibrary.org/obo/CHEBI_35610
T336 1082-1099 Chemical denotes immunosuppressant http://purl.obolibrary.org/obo/CHEBI_35705

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T39 720-733 http://purl.obolibrary.org/obo/GO_0032774 denotes RNA synthesis
T40 724-733 http://purl.obolibrary.org/obo/GO_0009058 denotes synthesis
T41 983-999 http://purl.obolibrary.org/obo/GO_0007623 denotes circadian rhythm
T42 993-999 http://purl.obolibrary.org/obo/GO_0048511 denotes rhythm
T43 1000-1005 http://purl.obolibrary.org/obo/GO_0030431 denotes sleep

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T21 916-933 Phenotype denotes polycystic kidney http://purl.obolibrary.org/obo/HP_0000113

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T173 0-101 Sentence denotes a The possible exposure mode of the HCoV-associated protein module to the pairwise drug combinations.
T174 102-317 Sentence denotes An effective drug combination will be captured by the “Complementary Exposure” pattern: the targets of the drugs both hit the HCoV–host subnetwork, but target separate neighborhoods in the human interactome network.
T175 318-421 Sentence denotes ZCA and ZCB denote the network proximity (Z-score) between targets (Drugs A and B) and a specific HCoV.
T176 422-1112 Sentence denotes SAB denotes separation score (see Materials and methods) of targets between Drug A and Drug B. b–d Inferred mechanism-of-action networks for three selected pairwise drug combinations: b sirolimus (a potent immunosuppressant with both antifungal and antineoplastic properties) plus dactinomycin (an RNA synthesis inhibitor for treatment of various tumors), c toremifene (first-generation nonsteroidal-selective estrogen receptor modulator) plus emodin (an experimental drug for the treatment of polycystic kidney), and d melatonin (a biogenic amine for treating circadian rhythm sleep disorders) plus mercaptopurine (an antimetabolite antineoplastic agent with immunosuppressant properties).